Introduction
Prostate cancer is the second most common cancer diagnosed in men worldwide and the fourth of all malignancies diagnosed. In fact, it contributes to 7.9% of all global malignancies in accordance with the World Health Organization 1 . The early detection and treatment of prostate cancer could impact significantly on progression of the disease and thus impact on the expenditure on medical treatments. 2 Prostate cancer is more commonly detected in men older than 60 years of age and the earlier detection and treatment 3 of this could aid in a country's national expenditure on health care. 4 This is particularly pertinent in the setting of Australia's Stage 4 aging population.(See Table 1 ) Diagnosis of prostate cancer in Australia is primarily performed through ultrasound-guided biopsy. This is through either transrectal or transperineal approaches. Globally prostate cancer incidence rates vary by more than 25-fold with Australia and New Zealand among the highest rates. 5 This is likely secondary to access to health-care services through public health programs. It is also estimated that 1.3 million new cases of prostate cancer will be diagnosed in 2018. 5 .
Australia has a well-established public health program, Medicare, which allows for billing and data collation of the number of procedures within their country. Because of this, we aimed to characterize the ultrasound-guided biopsy trends within this country by using this data from the Australian Government Medicare Benefits Schedule online database.
Method
A population study was performed as part of a project with ethics approval (ACT/HREC/ETHLR18.075).
Prostate biopsy numbers were obtained from the Australian Government Department of Health Medicare Benefits Schedule using the item numbers which code for ultrasound-guided prostate biopsy. Population data were obtained from the Australian Government Bureau of Statistics Census. Data were analyzed using Microsoft Excel.
A meta narrative review of the literature following the RAMSES guidelines 6 was performed to correlate trends within Australia for the introduction of new technologies for the detection of prostate cancer and policies and procedures from the major governing medical colleges in relation to prostate cancer. We also performed a review of the literature and policy announcements in Australia to assess the impact these may have had on the total number of prostatectomies performed. A literature search was performed through medical databases MEDLINE and EMBASE regarding key literature focused on the Australian guidelines in relation to prostate cancer surveillance and diagnosis. A thorough search of Australian medical colleges and government organizations was also carried out to complete the narrative review to ensure that no Australian policies or guidelines were excluded from the analysis. These were then graphically linked to the prostate biopsy trends in Australia.
Results
The 2016 census data showed the male population of Australia as 11,546,638, with 3,045,845 men aged 55 years and older in 2016; 18,285 ultrasound-guided biopsies were performed, with 16,586 being performed in men older than 55 years, resulting in a biopsy rate of 0.54% Over the course of the 17 years, the age-group of 55e64 years was the group with the highest biopsy numbers (n ¼ 143,730). In 2013, this transitioned to the age-group between 65 and 74 years. Biopsy numbers in the age-group 75e84 years also slowly increased from 2000 to 2009 and declined in 2010 and continued to slowly rise until 2017.
Discussion
Identification and characterization of prostate cancer to ensure treatment of clinically significant disease, minimization of overtreatment and minimization of biopsy related complications is a significant challenge. Following review of this data, we noticed important trends in ultrasound-guided prostate biopsies throughout the country. The most notable of which was the decline in the number of ultrasound-guided biopsies performed since 2009. This decrease in the number of biopsies performed was demonstrated in all age-groups at least immediately after 2009 with the >75 years age-group continuing to increase after this initial drop. Interestingly, it was also noted that the highest age-group biopsied transitioned in 2013 from 55e64 to 65e74 years. This could potentially be reflected in the process of active surveillance as repeat biopsy is unable to be differentiated from this data.
In March 2009, the New England Journal of Medicine published both the Screening and prostate cancer mortality in a randomized European Study (ERSPC) 8 and mortality results from a randomized prostate cancer screening trial (PLCO) 9 . The ERSPC trial came to the conclusion that prostate cancer screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of over diagnosis. The PLCO trial concluded that the rate of death from prostate cancer was very low and did not differ significantly 12 There has also been growing concern from the urology community in relation to the lack of PSA screening being performed. In July 2012, the US Preventive Services Task Force released a statement on prostate cancer screening stating against the use of PSA-based screening for prostate cancer regardless of age. 13 This reflects the similar stance of RACGP in relation to the results and recommendations from the PLCO trial. In Australia, multiparametric magnetic resonance imaging (mpMRI) of the prostate is commonly used by urologists and we hypothesized that this may have been the cause for lower rates of ultrasound-guided prostate biopsy. We noted in 2012, Prostate Imaging Reporting and Data System (PI-RADS) version1 14 was released and this could have had further impact on the biopsies decline until 2016. We hypothesize that this is because of the decrease in biopsies being performed on men with a PI-RADS score <3 as their risk of clinically significant prostate cancer is low. They have also released PI-RADS version 2 15 in 2016 and further analysis of trends will be required to assess the potential impact that this could have on future ultrasound-guided biopsies. Another influence on the diagnosis of prostate cancer in Australia was in 2014 when Pokorny et al.. 16 published an ultrasound-vs MRI-guided biopsy study MRI-targeted biopsies with cognitive or technical modalities have likely reduced the need for multiple biopsies in many patients. In addition, Thompson et al. 17 published in 2014 a prospective study that assessed mpMRI-guided biopsies to detect clinically significant prostate cancer. They showed that mpMRI reported by expert radiologists achieved a negative predictive value of 100% (confidence interval CI 82e100), 94% (CI 81e93) and 74% (CI 61e83) in PI-RADS 1, 2, and 3 respectively. 17 This is likely to have affected prostate cancer biopsy trends in as patients with a mpMRI PI-RADS score 3 may be unlikely to undergo biopsy. This led to the introduction of mpMRI Medicare rebate for prostate cancer screening in 2018.
The National Health and Medical Research Council approved the Prostate Cancer Foundation of Australia guidelines on PSA screening in 2016. 18 The general recommendation is that for those between the age of 50e69 years who decide to have PSA testing should undergo a blood test every 2 years. 18 guidelines follow the USANZ guidelines more closely and we will have to wait to see if this has an impact on the number of ultrasound-guided biopsies in the future. Unfortunately, we cannot extrapolate repeat biopsy from this data set and this could be the cause of age migration through active surveillance. This could potentially explain the age migration shift in 2013. The data set does no include whether or not the episode was the primary biopsy or a repeat biopsy. Patients before the introduction of mpMRI with a persistently raised PSA may have had multiple biopsies to ensure that clinically significant cancer was not missed. This could reflect the elevated numbers before 2009. With the introduction of mpMRI, for patients with a PI-RADS score 3 urologists may be more confident in avoiding repeat biopsy or even primary biopsy in patients with a raised PSA. More recently in June 2019, the 'NICE Guidance e Prostate cancer: diagnosis and management' was published with the recommendation that mpMRI should be offered as the first-line investigation for people with suspected clinically localized prostate cancer. 20 .
Conclusion
Interesting trends have been identified through this population study. Recognizable decreases in the number of biopsies performed since 2009e2010 are likely attributable to the introduction of PSA screening guidelines by both RACGP and USANZ. It also coincides with the release of the ERSPC and PLCO prostate cancer screening trials in 2009. It was also theorized that the introduction of mpMRI in Australia as a new tool used for the screening of prostate cancer may have also had an impact in the decreasing rates of ultrasoundguided prostate biopsy. With the introduction of government rebates for mpMRI as well as the National Institute for Health and Care Excellence (NICE) guidelines recommendations, it is envisaged that prostate biopsy numbers will continue to decrease with increasing availability of mpMRI.
